Vnitr Lek 2019, 65(12):788-793 | DOI: 10.36290/vnl.2019.137

Extermination of atherosclerosis not only in lower extremities

Jan Piťha1,2,*, Věra Boháčová3
1 Interní klinika 2. LF UK a FN v Motole, Praha
2 Centrum experimentální medicíny IKEM, Praha
3 Fórum zdravé výživy, z.s., Praha

Majority of patients with peripheral artery disease (PAD) are affected by coronary artery disease and other vascular complications, often fatal. PAD is, therefore, powerful indicator of a very high risk of death. The main risk factors are smoking and diabetes mellitus; both factors can be corrected very successfully, in theory. In most of patients suffering from PAD mixed dyslipidemia is found, which presents by moderately elevated LDL-cholesterol and triglyceride levels. However, since PAD patients are at a very high risk of cardiovascular death, even moderately elevated LDL-cholesterol levels are very dangerous and should be kept below 1.4 mmol/l. Therefore, these patients require a comprehensive intervention of all risk factors, smoking eradication, diabetes control, but most importantly, LDL-cholesterol reduction. In the following article practical approach how to get risk factors under control is presented.

Keywords: dyslipidemia; lifestyle management; peripheral artery disease; pharmacotherapy; risk factors

Received: November 3, 2019; Accepted: November 12, 2019; Published: December 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J, Boháčová V. Extermination of atherosclerosis not only in lower extremities. Vnitr Lek. 2019;65(12):788-793. doi: 10.36290/vnl.2019.137.
Download citation

References

  1. Roztocil K. Zásady péče o pacienty s intermitentními klaudikacemi. [The principles of care for patients with intermittent claudication]. Vnitř Lék 2010; 56(7): 724-726. Go to PubMed...
  2. Piťha J. Proč umírají pacienti s ICHDK na ICHS a proč často zbytečně? Interní Med 2017; 19(4): 179-185. Go to original source...
  3. Piťha J. Proč nebrzdit volný pád LDL-cholesterolu a nepomlouvat statiny. [Why not to interfere with LDL-cholesterol freefall and why not to talk badly about statins]. Vnitř Lék 2018; 64(12): 1169-1175. Go to original source...
  4. Kullo IJ, Rooke TW. Clinical practice. Peripheral Artery Disease. N Engl J Med 2016; 374(9): 861-871. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMcp1507631>. Go to original source... Go to PubMed...
  5. Murphy TP, Cutlip DE, Regensteiner JG et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol 2015; 65(10): 999-1009. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2014.12.043>. Go to original source... Go to PubMed...
  6. Ruiz-Canela M, Estruch R, Corella D et al. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA 2014; 311(4): 415-417. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2013.280618>. Go to original source... Go to PubMed...
  7. Karanja N, Lancaster KJ, Vollmer WM et al. Acceptability of sodium-reduced research diets, including the Dietary Approaches To Stop Hypertension diet, among adults with prehypertension and stage 1 hypertension. J Am Diet Assoc 2007; 107(9): 1530-1538. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jada.2007.06.013>. Go to original source... Go to PubMed...
  8. Piťha J, Boháčová V, Doubková K et al. Projekt intenzivního ovlivnění dyslipidémií u pacientů s ischemickou chorobou dolních končetin. Practicus 2016; 15(10): 9-11.
  9. Shalaeva EV, Saner H, Janabaev BB et al. Tenfold risk increase of major cardiovascular events after high limb amputation with non-compliance for secondary prevention measures. Eur J Prev Cardiol 2017; 24(7): 708-716. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487316687103>. Go to original source... Go to PubMed...
  10. Zvolská K, Králíková E. Centra pro závislé na tabáku v ČR v roce 2016. [Centers for tobacco-dependent in the Czech Republic in 2016]. Čas Lék Česk 2017; 156(1): 19-23. Go to PubMed...
  11. Dostupné z WWW: <www.nutriinfo.eu>.
  12. [Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies]. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014>. Go to original source... Go to PubMed...
  13. Barry E, Roberts S, Oke J et al. Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions. BMJ 2017; 356: i6538. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.i6538>. Go to original source... Go to PubMed...
  14. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60(2): 215-225. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125-016-4157-3>. Go to original source... Go to PubMed...
  15. Bonaca MP, Nault P, Giugliano RP et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 2018; 137(4): 338-350. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032235>. Go to original source... Go to PubMed...
  16. Jukema JW, Szarek M, Zijlstra LE et al. [ODYSSEY OUTCOMES Committees and Investigators]. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2019; 74(9): 1167-1176. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2019.03.013>. Go to original source... Go to PubMed...
  17. Bláha V, Bláha M, Lánská M et al. Postavení lipoproteinové aferézy v současnosti. [Position of lipoprotein apheresis in present]. Vnitř Lék 2015; 61(11): 958-964. Go to PubMed...
  18. Weiss N. A critical review on the use of lipid apheresis and rheopheresis for treatment of peripheral arterial disease and the diabetic foot syndrome. Semin Dial 2012; 25(2): 220-227. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1525-139X.2011.01036.x>. Go to original source... Go to PubMed...
  19. Dostupné z WWW: <http://wp.interna-cz.eu/specializovana-pracoviste-pro-lecbu-primarni-hypercholesterolemie-smisene-dyslipidemie/>.
  20. Madsen CM, Kamstrup PR, Langsted A et al. Lp(a) (Lipoprotein[a])-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol 2019: ATVBAHA119312951. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA.119.312951>. Go to original source... Go to PubMed...
  21. Poredos P, Jezovnik MK. Is aspirin still the drug of choice for management of patients with peripheral arterial disease? Vasa 2013; 42(2): 88-95. Dostupné z DOI: <http://dx.doi.org/10.1024/0301-1526/a000251>. Go to original source... Go to PubMed...
  22. Mohler ER. Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both? Catheter Cardiovasc Interv 2009; 74(Suppl 1): S1-S6. Dostupné z DOI: <http://dx.doi.org/10.1002/ccd.21995>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.